ProfileGDS5678 / 1424117_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 91% 89% 89% 88% 91% 91% 90% 90% 90% 90% 89% 91% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0630189
GSM967853U87-EV human glioblastoma xenograft - Control 27.3952491
GSM967854U87-EV human glioblastoma xenograft - Control 37.1432989
GSM967855U87-EV human glioblastoma xenograft - Control 47.1337689
GSM967856U87-EV human glioblastoma xenograft - Control 57.0057788
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1569891
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2082691
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1341690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1423390
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2885390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1771190
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1474389
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3446491
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0752489